Vortioxetine
Stage I, II or III Breast Cancer
University of MiamiSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
891 Active assets in the Stage I, II or III Breast Cancer cohort.
View all 50 →
Same molecule, other indications
Vortioxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →